ICU Medical, Inc. (ICUI) Stock Price & Analysis
ICU Medical, Inc. (ICUI) closed at USD 168.33 on Thursday, October 22, 2026, up 4.66% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 160.84; the Oct 22, 2026 session ranged USD 160.85–168.62 on volume of 241,697 shares. Market capitalization is $4.21B, with a 52-week range of USD 113.37–192.85 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:59 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ICUI.md
Key facts (ICUI)
- Last four reported quarters (through Jun 30, 2026): revenue $2.16B, net income $30.1M (1.4% margin), free cash flow $153M (SEC filings).
- Valuation: P/E 139.9x (avg 4853.9x at the last 1 fiscal year-ends).
- Earnings quality: non-operating income -$1.6M vs operating income $72.1M over the last four quarters; P/E excluding non-operating income ≈132.9x (estimate: non-operating income taxed at the company's 0% effective rate).
- Insider open-market sales, last ~7 months: 10 Form 4 filings, $7.5M; 7 not under a Rule 10b5-1 plan ($4.0M); 6 by opportunistic insiders (5 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 193.38 (range 178–210).
- Total return with dividends: 1Y +38.4% vs S&P 500 +14.9%; 5Y -25.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 2.15, revenue estimate $554M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ICUI)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.32B | $2.28B | $2.26B | $2.38B | $2.23B | $2.16B |
| Gross profit | $491M | $698M | $740M | $825M | $822M | — |
| Operating income | $123M | -$42.9M | $22.8M | $43.0M | $42.8M | $72.1M |
| Net income | $103M | -$74.3M | -$29.7M | -$118M | $732K | $30.1M |
| EPS (diluted) | $4.74 | -$3.11 | -$1.23 | -$4.83 | $0.03 | — |
| Free cash flow | $199M | -$152M | $82.3M | $125M | $91.8M | $153M |
| Gross margin | 37.3% | 30.6% | 32.8% | 34.6% | 36.8% | — |
| Operating margin | 9.4% | -1.9% | 1.0% | 1.8% | 1.9% | 3.3% |
| Net margin | 7.8% | -3.3% | -1.3% | -4.9% | 0.0% | 1.4% |
| Revenue growth | +3.6% | +73.2% | -0.9% | +5.4% | -6.3% | — |
| Cash + short-term investments | $567M | $213M | $255M | $309M | — | — |
| Total debt | $0K | $1.65B | $1.63B | $1.58B | $1.28B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ICUI)
P/E 139.9x · P/E ex non-operating (est.) ≈132.9x · P/S 1.9x · P/FCF 27.5x · P/B 2.0x · FCF yield 3.63% · Earnings yield 0.71%
P/E at fiscal year-ends: Dec 2025 4853.9x.
Insider sales (SEC Form 4, open-market, last ~7 months) (ICUI)
3 of 10 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-03 | Sanzone Virginia Ruth | VP, General Counsel | 4,856 | $819K | 25% | Yes (adopted June 8, 2026) | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-09-01 | Bonnell Brian Michael | Chief Financial Officer | 6,381 | $1.1M | 10.2% | Yes (adopted June 1, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-08-31 | Bonnell Brian Michael | Chief Financial Officer | 9,307 | $1.6M | 13% | Yes (adopted June 1, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-08-13 | Woolson Daniel | VP, GM-Infusion Capital | 5,417 | $982K | 24.1% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-12 | Sousa Ben | Chief Information Officer | 2,250 | $401K | 42.2% | No | Too little history (no open-market trades in 2023) |
| 2026-08-11 | Voigtlander Christian B. | Chief Operating Officer | 8,929 | $1.6M | 19.3% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-08-11 | Finney Elisha W | Director | 378 | $69K | 7.2% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-22 | Woolson Daniel | President | 2,123 | $281K | 8.6% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-14 | Sanzone Virginia Ruth | VP, General Counsel | 2,447 | $304K | 11.2% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
| 2026-05-12 | Greenberg David C. | Director | 2,424 | $298K | 20.8% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ICUI)
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 193.38 (low 178, high 210).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-07 | Piper Sandler | Target raised | Overweight | $163 → $195 |
| 2026-08-07 | BTIG | Target raised | Buy | $170 → $200 |
| 2026-08-07 | Needham | Target raised | Buy | $165 → $187 |
| 2026-07-21 | Keybanc | Target raised | Overweight | $164 → $182 |
Total return (dividends reinvested) (ICUI)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +38.4% | -25.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +38.5% | -5.7% |
| Volatility (annualized) | 35.4% | 38.9% |
| Max drawdown | -27.2% (Jan 2026→Apr 2026) | -66.8% (Nov 2021→Nov 2023) |
ICUI revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Infusion Consumables | $289.3M | 52.4% | +5.9% |
| Infusion Systems | $189.0M | 34.3% | +12.7% |
| Vital Care | $73.4M | 13.3% | -32.1% |
| Total revenue | $551.7M | 100% | — |
ICUI revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| UNITED STATES | $349.9M | 63.4% | +4.3% |
| EMEA | $95.1M | 17.2% | -4.0% |
| Asia Pacific | $55.6M | 10.1% | -4.7% |
| Other foreign countries | $51.1M | 9.3% | -8.7% |
| Total revenue | $551.7M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ICUI suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Otsuka Pharmaceutical Factory America | “All statements, other than statements of historical fact, contained in this Annual Report on Form 10-K, including, without limitation, statements regarding: our future results of operations and financial position, business strategy and approach; the anticipated benefits and costs associated with our purchase agreement with OPF (as defined below); expected capital expenditures; anticipated consumer demand; supply c…” |
Quoted from the company's 10-K filed Feb 19, 2026.
ICUI analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.15 | $2.08 | +3.2% | $553.9M | 7 |
| Next quarter (ends Dec 2026) | $2.23 | $2.20 | +1.8% | $561.6M | 7 |
| Current fiscal year (ends Dec 2026) | $8.75 | $8.16 | +7.3% | $2.19B | 8 |
| Next fiscal year (ends Dec 2027) | $9.65 | $9.30 | +3.7% | $2.29B | 8 |
ICUI options: expected move
Options price a move of about ±10.8% (±$18.20) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±6.4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 47.8% | ±10.8% |
| Dec 18, 2026 | 56 | 41.0% | ±13.0% |
| Feb 19, 2027 | 119 | 40.1% | ±18.3% |
| May 21, 2027 | 210 | 41.0% | ±24.8% |
30-day implied volatility 42.6% vs 27.8% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:59 UTC)
| Price | USD 168.33 |
|---|---|
| Change | ▲ 4.66% (up) |
| Previous Close | USD 160.84 |
| Open | USD 161.11 |
| Day Range | USD 160.85 – 168.62 |
| 52-Week Range | USD 113.37 – 192.85 |
| Volume | 241,697 shares |
| Market Cap | $4.21B |
| Exchange | NMS |
Technical Analysis (ICUI)
Nexqual's technical model rates ICUI "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:59 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 57.66 (neutral) |
| vs SMA50 | Above (USD 166.37) |
| MACD | 0.17 (positive) |
Analyst Ratings (ICUI)
Wall Street analysts rate ICUI "Buy" based on 8 analysts, with a mean price target of USD 193.38 (range USD 178–210), per Nexqual as of October 23, 2026 at 09:59 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 193.38 |
| High Target | USD 210 |
| Low Target | USD 178 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (ICUI)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 2.15 |
| Revenue Estimate | $553.93M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.37 vs est 1.91 ▲ beat |
| 2026-03-31 | USD 1.97 vs est 1.75 ▲ beat |
| 2025-12-31 | USD 1.91 vs est 1.69 ▲ beat |
| 2025-09-30 | USD 2.03 vs est 1.43 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:59 UTC.
Financials & Fundamentals (ICUI)
| Total Revenue | $2.16B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +0.50% |
| Gross Margin | +38.26% |
| Operating Margin | +7.53% |
| Profit Margin | +1.39% |
| ROE | +1.41% |
| Debt / Equity | 0.6 |
| Current Ratio | 2.43 |
| Total Cash | $302.64M |
| Total Debt | $1.29B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $152.83M (7.1% of revenue) |
Source: Nexqual, October 23, 2026 at 09:59 UTC.
Financial Health Score (ICUI)
Nexqual rates ICU Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:59 UTC.
| Growth | Weak — Revenue -7% YoY (annual), declining |
|---|---|
| Profitability | Solid — Gross margin 38%, operating 8% (last 12 months) |
| Balance Sheet | Strong — $303M cash vs $1.29B debt |
| Cash Flow | Solid — FCF $153M (last 4 quarters to Jun 2026, SEC), 7% margin |
| Efficiency | Weak — ROE 1%, ROA 1.9% |
Ownership (ICUI)
| Insider Ownership | +1.75% |
|---|---|
| Institutional Ownership | +115.91% |
| Shares Outstanding | 25.01M |
| Float | 24.56M |
| Short % of Float | +7.29% |
Source: Nexqual, October 23, 2026 at 09:59 UTC.
Leadership (ICUI)
ICU Medical, Inc. is led by Vivek Jain, CEO & Chairman of the Board, per Nexqual as of October 23, 2026 at 09:59 UTC.
| CEO & Chairman of the Board | Vivek Jain |
|---|---|
| President | Daniel Woolson |
| CFO & Treasurer | Brian Michael Bonnell |
| Chief Operating Officer | Christian B. Voigtlander |
| Vice President of Human Resources | Olivia Barrall |
Major Backers & Investors (ICUI)
Notable institutional backers of ICU Medical, Inc. include Jupiter Topco LLC, JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund, Fuller & Thaler Asset Management Inc., according to Nexqual as of October 23, 2026 at 09:59 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jupiter Topco LLC | 11.13% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 6.42% |
| Fuller & Thaler Asset Management Inc. | 5.19% |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 4.22% |
| Schroder Investment Management Group | 2.96% |
| Ameriprise Financial, Inc. | 2.76% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.02% |
| Vanguard Group | 10.37% |
| Dimensional Fund Advisors | 4.21% |
| State Street | 4.1% |
Source: Nexqual, October 23, 2026 at 09:59 UTC.
From ICU Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Our primary Infusion System products are: Large Volume Pump ("LVP") Hardware: •Plum Duo™ and Plum Solo™ precision infusion pumps (together, the "Plum precision pumps") are single-channel and dual-channel infusion pump systems that received FDA 510(k) clearance in April 2025.
Legal & Regulatory Risks (Item 1A, quoted)
- Our ability to market, distribute and sell our products in the U.S. and other countries may be adversely affected if our products fail to comply with the existing laws and regulations, and applicable requirements of the FDA, governmental agencies in other countries, and notified bodies.
- We currently market certain products that have received 510(k) clearance, and we may pursue 510(k) clearance for future products.
- The FDA's and other regulatory authorities' policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval or certification of our product candidates.
- The FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our future products under development or otherwise increase the costs associated with compliance.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVST | Envista Holdings Corporation | USD 23.97 | ▲ 3.36% |
| PLSE | Pulse Biosciences, Inc | USD 52.68 | ▲ 2.67% |
| MMED | MiniMed Group, Inc. | USD 18.29 | ▲ 2.75% |
| WRBY | Warby Parker Inc. | USD 25.67 | ▲ 0.16% |
| STVN | Stevanato Group S.p.A. | USD 19.5 | ▲ 3.61% |
| MMSI | Merit Medical Systems, Inc. | USD 93.94 | ▲ 2.78% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:59 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt